Be the first to like this
Kanzatec LLC, is representing Geneasys exclusively, to divest all the KeyLab patent applications and technology assets. The KeyLab portfolio, which may provide a strategic advantage to one of your clients represents a "Lab on a Chip"—a low cost DNA based diagnostic device (USB), that can be used anywhere, by anybody, using a smart phone, tablet or laptop.
Geneasys has a portfolio of 350+ US patent applications (plus PCT coverage), covering KeyLab, including alternative approaches and ring-fencing the core technology. 17 applications have been allowed already by the USPTO, with the remainder pending
The portfolio has priority dates of 2010 and provides the buyer with a broad set of applications that can be strategically prosecuted to attain excellent future patent protection.